IN2014DN10123A - - Google Patents
Info
- Publication number
- IN2014DN10123A IN2014DN10123A IN10123DEN2014A IN2014DN10123A IN 2014DN10123 A IN2014DN10123 A IN 2014DN10123A IN 10123DEN2014 A IN10123DEN2014 A IN 10123DEN2014A IN 2014DN10123 A IN2014DN10123 A IN 2014DN10123A
- Authority
- IN
- India
- Prior art keywords
- vectors
- methods
- dcs
- transgene
- transcription
- Prior art date
Links
- 239000013598 vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305566.7A EP2666477A1 (en) | 2012-05-23 | 2012-05-23 | Lentiviral vectors containing an MHC class I promoter |
| PCT/EP2013/059041 WO2013174630A1 (en) | 2012-05-23 | 2013-04-30 | Lentiviral vectors containing an mhc class i promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10123A true IN2014DN10123A (enExample) | 2015-08-21 |
Family
ID=48289150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10123DEN2014 IN2014DN10123A (enExample) | 2012-05-23 | 2013-04-30 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8951535B2 (enExample) |
| EP (2) | EP2666477A1 (enExample) |
| JP (1) | JP5938143B2 (enExample) |
| KR (1) | KR101774929B1 (enExample) |
| CN (1) | CN104736167B (enExample) |
| AU (1) | AU2013265586B2 (enExample) |
| BR (1) | BR112014028944B1 (enExample) |
| CA (1) | CA2873473C (enExample) |
| ES (1) | ES2498277T3 (enExample) |
| IL (1) | IL235705A (enExample) |
| IN (1) | IN2014DN10123A (enExample) |
| NZ (1) | NZ702345A (enExample) |
| PL (1) | PL2678032T3 (enExample) |
| PT (1) | PT2678032E (enExample) |
| SG (1) | SG11201407732SA (enExample) |
| WO (1) | WO2013174630A1 (enExample) |
| ZA (1) | ZA201408652B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016520316A (ja) * | 2013-06-03 | 2016-07-14 | テラベクティ | ＭＨＣクラスＩ、ＭＨＣクラスＩＩまたはβ２ミクログロブリン上流プロモーター配列を含有するレンチウイルスベクター |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| KR20220005208A (ko) | 2020-07-06 | 2022-01-13 | 주식회사 지씨셀 | 면역원성이 감소된 신규한 이식용 세포 |
| CN114107393A (zh) | 2021-04-07 | 2022-03-01 | 上海劲威生物科技有限公司 | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 |
| KR20240073177A (ko) * | 2022-11-10 | 2024-05-24 | 전남대학교산학협력단 | 다중에피토프 펩타이드를 포함하는 신경교종 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19720152A1 (de) * | 1997-05-02 | 1998-11-05 | Max Delbrueck Centrum | Retrovirales Vektorsystem zur Optimierung des Gentransfers und der Genexpression in primären humanen T-Lymphozyten |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| EP1092779B1 (en) * | 1999-10-11 | 2009-11-25 | Institut Pasteur | Lentiviral vectors for the preparation of immunotherapeutical compositions |
| HK1050210B (en) | 1999-10-12 | 2007-08-24 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US8222029B2 (en) | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| WO2009019612A2 (en) | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
-
2012
- 2012-05-23 EP EP12305566.7A patent/EP2666477A1/en not_active Ceased
-
2013
- 2013-04-30 CA CA2873473A patent/CA2873473C/en active Active
- 2013-04-30 KR KR1020147033419A patent/KR101774929B1/ko active Active
- 2013-04-30 CN CN201380026705.4A patent/CN104736167B/zh active Active
- 2013-04-30 IN IN10123DEN2014 patent/IN2014DN10123A/en unknown
- 2013-04-30 PL PL13720364T patent/PL2678032T3/pl unknown
- 2013-04-30 US US13/873,922 patent/US8951535B2/en active Active
- 2013-04-30 SG SG11201407732SA patent/SG11201407732SA/en unknown
- 2013-04-30 JP JP2015513076A patent/JP5938143B2/ja active Active
- 2013-04-30 PT PT137203642T patent/PT2678032E/pt unknown
- 2013-04-30 BR BR112014028944-1A patent/BR112014028944B1/pt active IP Right Grant
- 2013-04-30 AU AU2013265586A patent/AU2013265586B2/en active Active
- 2013-04-30 ES ES13720364.2T patent/ES2498277T3/es active Active
- 2013-04-30 NZ NZ702345A patent/NZ702345A/en unknown
- 2013-04-30 EP EP13720364.2A patent/EP2678032B1/en active Active
- 2013-04-30 WO PCT/EP2013/059041 patent/WO2013174630A1/en not_active Ceased
-
2014
- 2014-11-13 IL IL235705A patent/IL235705A/en active IP Right Grant
- 2014-11-25 ZA ZA2014/08652A patent/ZA201408652B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013174630A1 (en) | 2013-11-28 |
| ZA201408652B (en) | 2016-09-28 |
| CA2873473C (en) | 2019-05-07 |
| AU2013265586A1 (en) | 2014-12-11 |
| KR101774929B1 (ko) | 2017-09-19 |
| EP2678032B1 (en) | 2014-06-18 |
| CA2873473A1 (en) | 2013-11-28 |
| IL235705A0 (en) | 2015-01-29 |
| AU2013265586B2 (en) | 2015-09-03 |
| SG11201407732SA (en) | 2014-12-30 |
| US8951535B2 (en) | 2015-02-10 |
| HK1211837A1 (en) | 2016-06-03 |
| CN104736167A (zh) | 2015-06-24 |
| BR112014028944A2 (pt) | 2015-09-29 |
| BR112014028944B1 (pt) | 2020-11-10 |
| EP2666477A1 (en) | 2013-11-27 |
| PT2678032E (pt) | 2014-09-09 |
| CN104736167B (zh) | 2018-07-27 |
| JP2015518716A (ja) | 2015-07-06 |
| JP5938143B2 (ja) | 2016-06-22 |
| ES2498277T3 (es) | 2014-09-24 |
| IL235705A (en) | 2016-10-31 |
| US20140120132A1 (en) | 2014-05-01 |
| EP2678032A1 (en) | 2014-01-01 |
| PL2678032T3 (pl) | 2014-11-28 |
| NZ702345A (en) | 2016-03-31 |
| KR20150014472A (ko) | 2015-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
| MX2023001394A (es) | Genes del factor viii optimizados. | |
| MX354516B (es) | Vectores que codifican el factor de viabilidad de conos derivado de bastones. | |
| CA2817709C (en) | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | |
| IN2014CN04586A (enExample) | ||
| MX2015004649A (es) | Metodos de modificacion de celulas huesped. | |
| PE20142406A1 (es) | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna | |
| IN2014CN03468A (enExample) | ||
| MX355356B (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
| MX2014004539A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| MX363427B (es) | Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo. | |
| NZ602278A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| GB0917002D0 (en) | Improved shigella blebs | |
| MX2018010288A (es) | Sistema de transposon y metodos de uso. | |
| MX2015012171A (es) | Promotores constitutivos de soja. | |
| WO2021084277A3 (en) | Transcription regulatory elements | |
| IN2014DN10123A (enExample) | ||
| EP3998341A3 (en) | Adenoviral vectors | |
| AU2015247777A8 (en) | Codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) | |
| EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| PH12015500771A1 (en) | Novel fc gamma receptor iib variants | |
| GB201017519D0 (en) | Vaccines | |
| IN2014DN10111A (enExample) |